Waters Corp (WAT) KPIs and segments
Close on Nov 18, 2026Market cap $45.79BP/E 116.2Yield –
KPI & bộ phận
Chỉ số vận hành và bộ phận làm nên hoạt động của Waters · năm tài chính kết thúc ngày 31 tháng 12
Nhìn nhanh KPI của Waters: 45 chỉ số vận hành, trong đó có Total Unfulfilled Performance Obligations, Ending Deferred Revenue and Customer Advances Balance và Legacy Deferred Revenue & Customer Advances Maturity, lấy từ 941 tài liệu nguồn, cùng doanh thu theo bộ phận, sản phẩm và khu vực từ hồ sơ SEC. Mỗi số đều dẫn tới tài liệu gốc. Tất cả chỉ số hiện cả bảng; Cốt lõi chỉ giữ bộ phận và KPI nổi bật. Bảng bộ phận còn có cách xem lũy kế 12 tháng.
Biểu đồ đang trống. Tick vào ô cạnh bất kỳ chỉ số nào ở bảng dưới để vẽ — tick nhiều chỉ số để so sánh trên cùng một biểu đồ.
Bộ phận, KPI nổi bật và mọi chỉ số vận hành từ hồ sơ, thông cáo kết quả và bản trình bày.
| Thêm vào biểu đồ | Chỉ số | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Waters Analytical And Materials Sciences($M)5 | 756 | 686 | 709 | 609 | |||||||||
United States($M) | 226 | 204 | 210 | 200 | |||||||||
Europe($M) | 209 | 207 | 202 | 166 | |||||||||
Asia Other($M) | 156 | 133 | 145 | 125 | |||||||||
China($M) | 118 | 100 | 107 | 81 | |||||||||
Americas Other($M) | 47 | 42 | 45 | 37 | |||||||||
Waters Advanced Diagnostics($M)5 | 521 | 349 | 62 | 53 | |||||||||
United States($M) | 195 | 121 | 19 | 16 | |||||||||
Europe($M) | 184 | 132 | 23 | 19 | |||||||||
Asia Other($M) | 55 | 40 | 4 | 5 | |||||||||
Americas Other($M) | 47 | 30 | 6 | 3 | |||||||||
China($M) | 40 | 26 | 10 | 10 | |||||||||
Waters Biosciences($M)5 | 368 | 232 | 0 | 0 | |||||||||
United States($M) | 149 | 90 | 0 | 0 | |||||||||
Europe($M) | 112 | 73 | 0 | ||||||||||
China($M) | 48 | 27 | 0 | 0 | |||||||||
Asia Other($M) | 33 | 24 | 0 | 0 | |||||||||
Americas Other($M) | 26 | 18 | 0 | 0 | |||||||||
Product($M) | 1,220 | 919 | 603 | 500 | 473 | 401 | 571 | 462 | 435 | 376 | 541 | ||
Consumables($M) | 765 | 543 | 165 | 138 | |||||||||
Instrument systems($M) | 455 | 376 | 308 | 263 | |||||||||
Service($M) | 425 | 348 | 329 | 300 | 298 | 261 | 302 | 278 | 273 | 261 | 279 | ||
Waters Instrument Systems($M) | 355 | 282 | 253 | 212 | 341 | 265 | 235 | 191 | 322 | ||||
Waters Service($M) | 299 | 273 | 271 | 237 | 272 | 251 | 246 | 236 | 251 | ||||
Chemistry consumables($M) | 170 | 158 | 165 | 138 | 151 | 139 | 141 | 134 | 143 | ||||
TA Instrument Systems($M) | 78.1 | 59.6 | 55.6 | 50.5 | 78.9 | 57.8 | 58.8 | 50.7 | 74.8 | ||||
TA Service($M) | 30.3 | 26.9 | 26.9 | 23.9 | 29.5 | 26.9 | 27.1 | 24.3 | 27.8 | ||||
United States($M) | 570 | 415 | 275 | 245 | 229 | 216 | 263 | 236 | 232 | 203 | 255 | ||
Europe($M) | 505 | 412 | 316 | 237 | 225 | 185 | 279 | 210 | 197 | 188 | 254 | ||
Asia Other($M) | 244 | 197 | 168 | 156 | 149 | 130 | 162 | 151 | 137 | 122 | 278 | ||
China($M) | 206 | 153 | 116 | 114 | 117 | 91 | 111 | 100 | 100 | 85.7 | 108 | ||
Americas Other($M) | 120 | 90 | 57.3 | 47.6 | 51 | 40 | 58.0 | 43.0 | 42.5 | 38.3 | 48.8 | ||
Kỳ báo cáo trước đây (báo cáo lần cuối 2024)1 | |||||||||||||
Product($M) | 520 | 395 | 363 | 289 | 273 | 232 | 345 | 269 | 259 | 223 | 333 | ||
Service($M) | 214 | 193 | 207 | 183 | 177 | 153 | 179 | 170 | 161 | 152 | 168 | ||
Remaining performance obligations (RPO)($M) | 495 | 520 | 267 | 301 | 334 | 340 | 295 | 317 | 337 | ||||
Total Unfulfilled Performance Obligations (Remaining Performance Obligations)($M)3 | 617 | 634 | 359 | 392 | 427 | 430 | 332 | ||||||
Expected to Be Recognized Within 1 Year (<=12 Months)($M) | 509 | 531 | 280 | 312 | 341 | 349 | 263 | ||||||
Expected to Be Recognized in 13 to 24 Months($M) | 70 | 69 | 40 | 41.9 | 45.9 | 42.1 | 38 | ||||||
Expected to Be Recognized in 25 Months and Beyond($M) | 38 | 34 | 38.2 | 38.3 | 40.6 | 39.3 | 31.2 | ||||||
Ending Deferred Revenue and Customer Advances Balance($M)3 | 603 | 592 | 345 | 382 | 421 | 421 | 320 | 358 | 383 | 407 | 324 | ||
Beginning Deferred Revenue and Customer Advances Balance($M) | 345 | 345 | 320 | 320 | 320 | 324 | 324 | 324 | |||||
Revenue Recognized from Beginning Deferred Revenue Balance($M) | 187 | 195 | 249 | 202 | 125 | 242 | 192 | 104 | |||||
Net Revenue Deferred During the Period($M) | 296 | 323 | 310 | 303 | 226 | 277 | 252 | 188 | |||||
Legacy Deferred Revenue & Customer Advances Maturity Schedule Total (Through Q3 2024)($M)2 | 358 | 383 | 407 | 324 | |||||||||
Total Point-in-Time Revenue($M)1 | 1,340 | 1,020 | 715 | 595 | 573 | 482 | 674 | 553 | 527 | 460 | 644 | ||
Service Revenue — Time and Materials (Point-in-Time)($M) | 120 | 101 | 111 | 94.9 | 100 | 81 | 103 | 91 | 92.1 | 83.3 | 103 | ||
Service & Software Maintenance Contracts Revenue (Over-Time)($M) | 305 | 247 | 218 | 205 | 198 | 180 | 199 | 187 | 181 | 177 | 176 | ||
Total Disaggregated Net Sales (Note 2)($M) | 1,645 | 1,267 | 932 | 800 | 771 | 662 | 873 | 740 | 709 | 637 | 820 | ||
Analytical Sciences Division (ASD) Revenue($M)5 | 703 | 669 | 607 | 649 | 627 | 534 | |||||||
ASD — Instruments Revenue($M)2 | 282 | 240 | 210 | 257 | 229 | 194 | |||||||
ASD Instruments Reported Revenue Growth (YoY)(%) | 9.0% | 5.0% | 8.0% | ||||||||||
ASD Instruments Constant Currency Revenue Growth (YoY)(%) | 10.0% | 8.0% | 8.0% | ||||||||||
ASD — Service Revenue($M)2 | 265 | 267 | 253 | 249 | 248 | 216 | |||||||
ASD Service Reported Revenue Growth (YoY)(%) | 6.0% | 8.0% | 17.0% | ||||||||||
ASD Service Constant Currency Revenue Growth (YoY)(%) | 8.0% | 9.0% | 14.0% | ||||||||||
ASD — Chemistry Consumables Revenue($M)2 | 157 | 162 | 144 | 143 | 150 | 124 | |||||||
ASD Chemistry Reported Revenue Growth (YoY)(%) | 10.0% | 8.0% | 16.0% | ||||||||||
ASD Chemistry Constant Currency Revenue Growth (YoY)(%) | 12.0% | 10.0% | 13.0% | ||||||||||
ASD Reported Revenue Growth (YoY)(%) | 8.0% | 7.0% | 14.0% | ||||||||||
ASD Constant Currency Revenue Growth (YoY)(%) | 9.0% | 9.0% | 12.0% | ||||||||||
Waters Biosciences Division (WBD) Revenue (Comparable Basis)($M)3 | 396 | 368 | 232 | 387 | 358 | 217 | |||||||
WBD — Flow Cytometry Research Solutions Revenue($M)1 | 214 | 198 | 131 | 212 | 201 | 122 | |||||||
WBD Flow Research Comparable Revenue Growth (YoY)(%) | 1.0% | -2.0% | 7.0% | ||||||||||
WBD — Flow Cytometry Clinical Solutions Revenue($M)1 | 182 | 170 | 102 | 174 | 157 | 95 | |||||||
WBD Flow Clinical Comparable Revenue Growth (YoY)(%) | 4.0% | 8.0% | 7.0% | ||||||||||
WBD Total Comparable Revenue Growth (YoY)(%) | 2.0% | 3.0% | 7.0% | ||||||||||
Advanced Diagnostics Division (ADx) Revenue (Comparable Basis)($M)3 | 575 | 521 | 349 | 64 | 62 | 53 | |||||||
ADx — Acquired Diagnostic Solutions Total Revenue (Comparable Basis)($M)3 | 500 | 449 | 288 | 498 | 425 | 268 | |||||||
ADx — Microbiology Sub-Unit Revenue (BACTEC, Kiestra, Phoenix, Prepared Media)($M)1 | 346 | 319 | 203 | 334 | 306 | 185 | |||||||
ADx Microbiology Comparable Revenue Growth (YoY)(%) | 4.0% | 4.0% | 10.0% | ||||||||||
ADx — Molecular Diagnostics (MDx) & Point of Care (PoC) Sub-Unit Revenue($M)1 | 154 | 129 | 84 | 164 | 119 | 83 | |||||||
ADx Molecular Dx & Point of Care Comparable Revenue Growth (YoY)(%) | -6.0% | 9.0% | 2.0% | ||||||||||
ADx Diagnostic Solutions Comparable Revenue Growth (YoY)(%) | 0.0% | 5.0% | 8.0% | ||||||||||
ADx — Clinical Business Unit (Organic LC-MS Diagnostics) Revenue($M)2 | 75 | 72 | 61 | 64 | 62 | 53 | |||||||
ADx Clinical Business Unit Reported Revenue Growth (YoY)(%) | 17.0% | 15.0% | 16.0% | ||||||||||
ADx Clinical Business Unit Constant Currency Revenue Growth (YoY)(%) | 18.0% | 14.0% | 14.0% | ||||||||||
ADx Total Comparable Revenue Growth (YoY)(%) | 2.0% | 7.0% | 9.0% | ||||||||||
Materials Sciences Division (MSD / TA Instruments) Revenue($M)4 | 93 | 87 | 79 | 87 | 82 | 75 | |||||||
MSD — Instruments Revenue($M)2 | 63 | 59 | 52 | 60 | 56 | 51 | |||||||
MSD Instruments Reported Revenue Growth (YoY)(%) | 6.0% | 6.0% | 2.0% | ||||||||||
MSD Instruments Constant Currency Revenue Growth (YoY)(%) | 8.0% | 9.0% | -2.0% | ||||||||||
MSD — Service Revenue($M)2 | 29 | 29 | 27 | 27 | 27 | 24 | |||||||
MSD Service Reported Revenue Growth (YoY)(%) | 8.0% | 6.0% | 13.0% | ||||||||||
MSD Service Constant Currency Revenue Growth (YoY)(%) | 9.0% | 7.0% | 10.0% | ||||||||||
MSD Reported Revenue Growth (YoY)(%) | 7.0% | 6.0% | 6.0% | ||||||||||
MSD Constant Currency Revenue Growth (YoY)(%) | 9.0% | 8.0% | 2.0% | ||||||||||
Organic Waters Revenue (Excluding Acquired BDS Business)($M)3 | 871 | 828 | 747 | ||||||||||
Organic Reported Revenue Growth (YoY)(%) | 9.0% | 7.0% | 13.0% | ||||||||||
Organic Constant Currency Revenue Growth (YoY)(%) | 10.0% | 9.0% | 11.0% | ||||||||||
Acquired BDS Business Revenue Contribution($M) | 896 | 817 | 520 | ||||||||||
Americas Regional Revenue($M) | 749 | 690 | 505 | 332 | 293 | 280 | 256 | 321 | 279 | 275 | 241 | 304 | |
Asia Regional Revenue($M) | 495 | 450 | 350 | 284 | 270 | 266 | 221 | 273 | 251 | 237 | 208 | 262 | |
Adjusted Non-GAAP Operating Income($M)7 | 532 | 462 | 300 | 328 | 243 | 225 | 169 | 309 | 228 | 207 | 172 | 286 | |
Adjusted Non-GAAP Operating Margin(%) | 30.1% | 28.1% | 23.6% | 35.2% | 30.3% | 29.1% | 25.5% | 35.5% | 30.8% | 29.2% | 27.0% | 34.9% | |
Adjusted Non-GAAP Gross Profit($M) | 985 | 925 | 693 | ||||||||||
Adjusted Non-GAAP Gross Margin(%) | 55.8% | 56.2% | 54.7% | ||||||||||
Adjusted Non-GAAP Net Income($M) | 404 | 301 | 222 | 271 | 203 | 176 | 134 | 244 | 174 | 156 | 131 | 215 | |
Adjusted Non-GAAP Diluted EPS($) | 4.10 | 3.05 | 2.70 | 4.53 | 3.40 | 2.95 | 2.25 | 4.10 | 2.93 | 2.63 | 2.21 | 3.62 | |
Adjusted Free Cash Flow (Non-GAAP)($M) | 68 | 202 | -42 | 160 | 159 | 234 | |||||||
Additions to Property, Plant, Equipment and Software Capitalization($M) | 43 | 49 | 39 | 25 | 23 | 26 | |||||||
U.S. FDA 510(k) Medical Device Clearances (Waters & Acquired BD Diagnostic Systems) | 1 | 5 | 2 | 3 | 6 | 6 | 3 | 3 | 1 | 0 | 3 | 4 | |
Total Inventories($M)3 | 1,377 | 1,496 | 572 | 573 | 541 | 512 | 477 | 519 | 523 | 539 | 516 | ||
Raw Materials Inventory($M) | 373 | 373 | 235 | 242 | 236 | 237 | 227 | 241 | 236 | 242 | 234 | ||
Work in Progress (WIP) Inventory($M) | 180 | 202 | 28 | 33.9 | 33.3 | 29.8 | 21.8 | 23.6 | 25 | 23.8 | 20.2 | ||
Finished Goods Inventory($M) | 824 | 921 | 309 | 297 | 272 | 245 | 228 | 254 | 262 | 273 | 262 | ||
Product Warranty Liability — Ending Balance($M)2 | 21 | 22 | 12 | 11.6 | 12 | 12 | 12 | 10.5 | 10.4 | 10.9 | 12.1 | ||
Warranty Accruals for Warranties Issued During Period($M) | 9 | 3 | 2.60 | 1.70 | 2 | 1 | 3.40 | 1.90 | 1.40 | 0.50 | 2.90 | ||
Warranty Settlements and Repair Costs Incurred($M) | 10 | 4 | 2 | 1.70 | 2 | 1 | 2.30 | 1.90 | 1.80 | 1.70 | 2 | ||
Property, Plant and Equipment, Net2 | |||||||||||||
Depreciation Expense on Property, Plant and Equipment($M) | 35 | 36 | 21.9 | 22.2 | 22 | 22 | 22.3 | 20.3 | 22.2 | 22.1 | 22.4 | ||
Amortization Expense of Purchased Intangible Assets($M) | 266 | 171 | 31 | 30 | 29 | 28 | 26 | 28 | 25 | 26 | 25 | ||
Operating Lease Right-of-Use (ROU) Assets($M)3 | 366 | 356 | 81 | 76.4 | 79.3 | 77.8 | 74.2 | 76.6 | 81.1 | 81.1 | 84.6 | ||
Operating Lease Liabilities — Current($M) | 51 | 53 | 31 | 28.5 | 28.7 | 27.3 | 25.5 | 25.3 | 26.4 | 26.9 | 27.8 | ||
Operating Lease Liabilities — Noncurrent($M) | 317 | 302 | 53 | 50.5 | 52.7 | 52.2 | 50.3 | 53.2 | 56.3 | 55.9 | 58.9 | ||
Operating Lease Weighted-Average Discount Rate(%) | 4.1% | 3.8% | 3.9% | 4.4% | 4.2% | ||||||||
Total Global Employees (Headcount)1 | |||||||||||||
Employee Stock Purchase Plan (ESPP) Issuance Value($M) | 4 | 2 | 2.60 | 2.80 | 3 | 2 | 2.40 | 2.60 | 2.80 | 2 | 2.40 | ||
Legacy Revenue by Customer Class — Pharmaceutical($M)2 | 541 | 480 | 462 | 391 | 499 | 430 | 416 | 374 | 464 | ||||
Pharmaceutical Reported Revenue Growth (YoY)(%) | 8.0% | 12.0% | 11.0% | 5.0% | 8.0% | 2.0% | -3.0% | -3.0% | -6.0% | ||||
Pharmaceutical Constant Currency Revenue Growth (YoY)(%) | 7.0% | 11.0% | 11.0% | 8.0% | 10.0% | 3.0% | -4.0% | -6.0% | -11.0% | ||||
Legacy Revenue by Customer Class — Industrial (Chemical, Materials, Food & Environmental)($M)2 | 285 | 236 | 238 | 203 | 264 | 228 | 221 | 195 | 260 | ||||
Industrial Reported Revenue Growth (YoY)(%) | 8.0% | 3.0% | 7.0% | 4.0% | 1.0% | 9.0% | -4.0% | -7.0% | -3.0% | ||||
Industrial Constant Currency Revenue Growth (YoY)(%) | 8.0% | 4.0% | 6.0% | 6.0% | 2.0% | 7.0% | -4.0% | -7.0% | -4.0% | ||||
Legacy Revenue by Customer Class — Academic and Government($M)2 | 107 | 84.4 | 71.7 | 67.3 | 110 | 82.4 | 71.4 | 67.3 | 95.5 | ||||
Academic & Government Reported Revenue Growth (YoY)(%) | -2.0% | 2.0% | 0.0% | 0.0% | 15.0% | 2.0% | -15.0% | -25.0% | -2.0% | ||||
Academic & Government Constant Currency Revenue Growth (YoY)(%) | -3.0% | 1.0% | -3.0% | 3.0% | 16.0% | 0.0% | -16.0% | -30.0% | -9.0% | ||||
Legacy Waters Operating Segment Revenue (Through FY2025)($M)2 | 824 | 713 | 689 | 587 | 764 | 656 | 623 | 562 | 717 | ||||
Legacy Waters Segment Reported Growth (YoY)(%) | 8.0% | 9.0% | 11.0% | 5.0% | 7.0% | 4.0% | -5.0% | -7.0% | -5.0% | ||||
Legacy Waters Segment Constant Currency Growth (YoY)(%) | 7.0% | 9.0% | 10.0% | 8.0% | 8.0% | 4.0% | -6.0% | -10.0% | -9.0% | ||||
Legacy TA Operating Segment Revenue (Through FY2025)($M)2 | 108 | 86.5 | 82.5 | 74.4 | 108 | 84.7 | 86 | 74.9 | 103 | ||||
Legacy TA Segment Reported Growth (YoY)(%) | 0.0% | 2.0% | -4.0% | -1.0% | 6.0% | 3.0% | -2.0% | -9.0% | -1.0% | ||||
Legacy TA Segment Constant Currency Growth (YoY)(%) | 0.0% | 2.0% | -6.0% | 1.0% | 7.0% | 2.0% | 0.0% | -9.0% | -2.0% | ||||
Legacy Total Recurring Revenue (Service + Chemistry, Through FY2025)($M)2 | 500 | 458 | 463 | 399 | 453 | 417 | 415 | 395 | 422 | ||||
Legacy Recurring Revenue Reported Growth (YoY)(%) | 10.0% | 10.0% | 12.0% | 1.0% | 7.0% | 6.0% | 4.0% | 3.0% | 7.0% | ||||
Legacy Recurring Revenue Constant Currency Growth (YoY)(%) | 9.0% | 9.0% | 11.0% | 4.0% | 9.0% | 7.0% | 5.0% | 3.0% | 5.0% | ||||
Legacy Single-Segment Significant Expenses — Labor in S&A and R&D (ASU 2023-07, Through FY2025)($M)3 | 164 | 164 | 164 | 152 | 152 | 144 | 147 | 154 | |||||
Legacy Single-Segment — Material Purchases in Cost of Sales($M) | 189 | 135 | 113 | 102 | 187 | 135 | 126 | 109 | |||||
Legacy Single-Segment — Labor Costs in Cost of Sales($M) | 103 | 100 | 96.2 | 88.4 | 91.1 | 88.1 | 85.4 | 86.4 | |||||
Legacy Single-Segment — Other Segment Expenses($M) | 206 | 208 | 209 | 168 | 150 | 162 | 162 | 155 | |||||
Consolidated Net Sales (GAAP)($M)11 | 1,645 | 1,267 | 932 | 800 | 771 | 662 | 873 | 740 | 709 | 637 | 820 | ||
Cost of Product Sales (GAAP)($M) | 700 | 524 | 241 | 211 | 200 | 169 | 226 | 193 | 176 | 153 | 207 | ||
Cost of Service Sales (GAAP)($M) | 211 | 155 | 122 | 117 | 121 | 108 | 123 | 108 | 112 | 109 | 111 | ||
Selling and Administrative Expenses (GAAP)($M) | 405 | 387 | 240 | 214 | 198 | 174 | 173 | 169 | 173 | 175 | 180 | ||
Research and Development Expenses (GAAP)($M) | 122 | 96 | 46.9 | 53.6 | 49 | 47 | 46.9 | 45.3 | 46.2 | 44.6 | 44.4 | ||
Consolidated Operating Income (GAAP)($M) | -86 | -47 | 271 | 192 | 188 | 152 | 292 | 211 | 189 | 134 | 264 | ||
Interest Expense (GAAP)($M) | 60 | 48 | 14.3 | 26.6 | 15 | 14 | 19 | 21.4 | 23.7 | 25.5 | 30.7 | ||
Income Before Income Taxes (GAAP)($M) | -141 | -88 | 264 | 170 | 178 | 143 | 277 | 194 | 169 | 115 | 238 | ||
Provision for Income Taxes (GAAP)($M) | -5 | -16 | 39 | 21.2 | 31 | 22 | 45.6 | 32.1 | 26.7 | 12.7 | 21.4 | ||
Consolidated Net Income (GAAP)($M) | -136 | -72 | 225 | 149 | 147 | 121 | 231 | 162 | 143 | 102 | |||
GAAP Diluted EPS($) | -1.39 | -0.87 | 3.77 | 2.50 | 2.47 | 2.03 | 3.88 | 2.71 | 2.40 | 1.72 | 3.65 | ||
Weighted-Average Diluted Shares Outstanding(M) | 98,204,000 | 82,139,000 | 59,763 | 59,622 | 59,656,000 | 59,711,000 | 59,645 | 59,504 | 59,451 | 59,431 | 59,311 | ||
Geographic Net Sales — United States($M)2 | 570 | 415 | 275 | 245 | 229 | 216 | 263 | 236 | 232 | 203 | 255 | ||
Geographic Net Sales — Total Americas($M) | 690 | 505 | 332 | 293 | 280 | 256 | 321 | 279 | 275 | 241 | 304 | ||
Geographic Net Sales — Total Asia($M) | 450 | 350 | 284 | 270 | 266 | 221 | 273 | 251 | 237 | 208 | 262 | ||
Total Assets (GAAP)($M)8 | 24,751 | 24,531 | 5,077 | 4,863 | 4,718 | 4,592 | 4,554 | 4,512 | 4,449 | 4,509 | 4,627 | ||
Cash and Cash Equivalents($M) | 539 | 462 | 588 | 459 | 367 | 383 | 325 | 331 | 326 | 337 | 395 | ||
Accounts Receivable, Net($M) | 1,987 | 673 | 829 | 749 | 730 | 713 | 733 | 670 | 610 | 626 | 702 | ||
Inventories (Balance Sheet)($M) | 1,377 | 1,496 | 572 | 573 | 541 | 512 | 477 | 519 | 523 | 539 | 516 | ||
Property, Plant and Equipment, Net (Balance Sheet)($M) | 1,489 | 1,520 | 642 | 637 | 645 | 643 | 651 | 643 | 636 | 634 | 639 | ||
Goodwill($M) | 9,421 | 9,317 | 1,340 | 1,338 | 1,338 | 1,300 | 1,296 | 1,307 | 1,298 | 1,298 | 1,305 | ||
Purchased Intangible Assets, Net($M) | 8,521 | 8,776 | 558 | 571 | 579 | 561 | 568 | 592 | 596 | 611 | 629 | ||
Total Liabilities($M) | 9,556 | 9,239 | 2,515 | 2,532 | 2,558 | 2,629 | 2,725 | 2,909 | 3,037 | 3,252 | 3,477 | ||
Total Stockholders' Equity($M) | 15,195 | 15,292 | 2,562 | 2,331 | 2,160 | 1,962 | 1,829 | 1,603 | 1,412 | 1,257 | 1,150 | ||
Net Cash Provided by Operating Activities (GAAP)($M)2 | 201 | -3 | 165 | 187 | 41 | 260 | 240 | 205 | 54.5 | 263 | 230 | ||
Stock-Based Compensation Expense($M) | 25 | 20 | 14.5 | 13.6 | 13 | 13 | 11.7 | 10.6 | 11.4 | 10.9 | 4.60 | ||
Repurchases of Common Stock($M) | 2 | 12 | 0.10 | 0.50 | -0 | 14 | 0.10 | 0.10 | 0.20 | 13.1 | -0.20 | ||
1 chỉ số không có số liệu trong 12 quý gần nhất — .
In nghiêng là số StockData tự tính từ số đã báo cáo (rê chuột để xem công thức). Số có gạch chân chấm là số đọc từ câu chữ trong thông cáo kết quả và bản trình bày; rê chuột để xem đúng câu đó. Tick vào một dòng để thêm vào biểu đồ phía trên (tối đa 8 đường).
Phương pháp và các chỉ số bị loại
- Các dòng ở Cốt lõi lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K và 10-Q (XBRL), có liên kết tới từng hồ sơ. Số quý 4 bằng cả năm tài chính trừ chín tháng đầu (hiện bằng chữ in nghiêng).
- Core Operational KPIs (Groups 1-3): Unfulfilled Performance Obligations (contract backlog by maturity horizon: <=12 months, 13-24 months, 25+ months) and Deferred Revenue Rollforward from Note 2; ASC 606 Revenue by Recognition Timing (Point-in-Time Instruments, Chemistry Consumables, and Time-and-Materials Service vs. Over-Time Service & Software Maintenance Contracts); and Post-Merger Sub-Division Revenue across Analytical Sciences (ASD), Biosciences (WBD Flow Research & Flow Clinical), Advanced Diagnostics (ADx Microbiology, Molecular Dx & PoC, and Clinical Business Unit), and Materials Sciences (MSD).
- Period Derivations: Flow metrics disclosed for three-month Q1-Q3 and cumulative 6M/9M in Form 10-Q alongside full-year figures in Form 10-K (Point-in-Time vs. Over-Time revenue disaggregation, ASU 2023-07 significant segment expenses, warranty accruals/settlements, depreciation, intangible amortization, and GAAP cash flows) include derived Q4 = full year (10-K) − nine months (10-Q) and Q2/Q3 = YTD − prior YTD.
- February 9, 2026 BDS Merger & Segment Reorganization: On February 9, 2026 (Q1 2026), Waters completed the Reverse Morris Trust acquisition of Becton, Dickinson and Company's Biosciences & Diagnostic Solutions (BDS) business and reorganized its reporting into four operating divisions (ASD, WBD, ADx, MSD). Standalone audited financials of the acquired BDS business (FY2023-FY2025) are presented in Group 7, and pre-merger legacy series (Waters vs. TA divisions and Pharmaceutical/Industrial/Academic customer classes through FY2025) are preserved in Group 8.
- Q3 2026 vs. Q2 2026 Reporting Cadence: Form 8-K Q3 2026 earnings release, Q3 2026 investor presentation, and openFDA 510(k) clearances are reported through Q3 2026 (ended September 27, 2026), while Form 10-Q footnote schedules (Note 2 RPO, deferred revenue rollforward, recognition timing, inventories by stage, and warranty rollforward) are reported through Q2 2026.
Không hiện vì thiếu các kỳ gần đây (18)
- Ending Deferred Revenue and Customer Advances Balance › Deferred Revenue Acquired in Business Combinations
- Analytical Sciences Division (ASD) Revenue › ASD — Pharmaceutical Customer Revenue
- Analytical Sciences Division (ASD) Revenue › ASD — Non-Pharmaceutical Customer Revenue
- Organic Waters Revenue (Excluding Acquired BDS Business) › Acquired BDS Business Comparable Revenue Growth (YoY)
- GLP-1 Testing Incremental Revenue
- PFAS Testing Incremental Revenue
- India Generics Incremental Revenue
- Total Scope 1 & 2 Greenhouse Gas Emissions (ktCO2e)
- Total Energy Consumption (MWh)
- Municipal Water Withdrawal (Cubic Meters)
- Total Operational Waste Generated (Metric Tons)
- Total Recordable Incident Rate (TRIR per 100 FTE)
- Consolidated Net Sales (GAAP) › Consolidated Cost of Sales (GAAP)
- Consolidated Net Sales (GAAP) › Consolidated Gross Profit (GAAP)
- Geographic Net Sales — United States › Geographic Net Sales — Japan (Discontinued Separate Disclosure After Q1 2024)
- Net Cash Provided by Operating Activities (GAAP) › Capital Expenditures (PP&E and Software)
- Note 13 Analytical & Materials Sciences — China Revenue
- Note 13 Reportable Segments — Material Purchases
Dữ liệu cập nhật 2026-11-08.
Mỗi KPI một trang riêng
Đầy đủ lịch sử, biểu đồ, nguồn và cách trích dẫn cho từng chỉ số
1. Unfulfilled Performance Obligations (RPO) & Deferred Revenue Rollforward
2. Revenue by Recognition Timing — Point-in-Time vs. Over-Time Contracts
3. Operating Divisions & Sub-Division Disaggregation (ASD, WBD, ADx, MSD)
4. Organic Revenue Bridge, Regional Sales & Non-GAAP Profitability
5. Commercial Execution, Regional End-Market Mix & FDA 510(k) Clearances
- Service Plan Attachment Rate (% of Active Installed Base) (%)3 kỳ
- eCommerce Adoption (% of Chemistry Consumables Revenue) (%)3 kỳ
- Contract Organizations (CDMO / CRO) Share of Pharmaceutical Revenue (%)3 kỳ
- Pharmaceutical Revenue — Americas ($M)2 kỳ
- Non-Pharmaceutical (Industrial & Academic/Gov) Revenue — Total ($M)2 kỳ
- U.S. FDA 510(k) Medical Device Clearances (Waters & Acquired BD Diagnostic Systems)35 kỳ
6. Inventories by Stage, Warranty Rollforward, PP&E, Leases & Global Workforce
7. Acquired Subsidiary Standalone Operations — BDS Business (Augusta SpinCo Corp., Pre-Merger)
8. Pre-Merger Legacy Segments (Waters vs. TA), Customer Classes & Significant Expenses (Through FY2025)
- Legacy Revenue by Customer Class — Pharmaceutical ($M)32 kỳ
- Legacy Revenue by Customer Class — Industrial (Chemical, Materials, Food & Environmental) ($M)32 kỳ
- Legacy Revenue by Customer Class — Academic and Government ($M)32 kỳ
- Legacy Waters Operating Segment Revenue (Through FY2025) ($M)23 kỳ
- Legacy TA Operating Segment Revenue (Through FY2025) ($M)23 kỳ
- Legacy Total Recurring Revenue (Service + Chemistry, Through FY2025) ($M)23 kỳ
- Legacy Single-Segment Significant Expenses — Labor in S&A and R&D (ASU 2023-07, Through FY2025) ($M)8 kỳ
9. Executive Compensation, Pay vs. Performance & CEO Pay Ratio (DEF 14A)
10. Financial Statement & Geographic Segment Context (GAAP)
Tài liệu nguồn mới nhất
Các tài liệu được trích nhiều nhất cho số liệu mới nhất của Waters
- Q4 2025 Form 8-K (Item 2.02 Earnings Release) ↗
- Q3 2026 Form 8-K (Item 2.02 Earnings Release) ↗
- Form 8-K EX-99.2 (2026-02-09) — BDS Business Audited Combined Financial Statements ↗
- SEC 10-Q (filed 2026-08-11, acc 0001193125-26-344691) ↗
- Q2 2026 Form 10-Q (Segment Footnote — Revenue Timing) ↗
- FY2025 Form 10-K (Segment Footnote — Revenue Timing) ↗
- Q4 2025 Earnings Presentation (2026-02-09), Slide 6 ↗
- SEC 10-K (filed 2026-02-23, acc 0001193125-26-062604) ↗
- Q3 2026 Earnings Presentation (2026-11-03), Slide 27 ↗
- Q4 2025 Earnings Presentation (2026-02-09), Slide 20 ↗
- U.S. FDA openFDA 510(k) Medical Device Clearances Database ↗
- Q2 2026 Form 10-Q (Note — Inventories) ↗
See a number that looks wrong?